Last reviewed · How we verify

Heart Failure — Treatment Landscape & Competitive Intelligence

Heart Failure (Cardiovascular) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Cardiovascular 5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Heart Failure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Inpefa SOTAGLIFLOZIN Lexicon Pharms Inc Sodium-Glucose Cotransporter 2 Inhibitor [EPC] Sodium/glucose cotransporter 2 2023-01-01
Verquvo VERICIGUAT Merck & Co. Soluble Guanylate Cyclase Stimulator [EPC] Guanylate cyclase soluble subunit beta-1 2021-01-01
Candesartan Cilexetil CILEXETIL Alembic Ace Inhibitor 2021-01-01
olmesartan medoxomil-hydrochlorothiazide OLMESARTAN Cosette Thiazide Diuretic [EPC] 2019-01-01
Lisinopril/HCTZ HCTZ Direct_Rx Thiazide Diuretic [EPC]

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Alembic · 1 drug in Heart Failure
  2. Cosette · 1 drug in Heart Failure
  3. Direct_Rx · 1 drug in Heart Failure
  4. Lexicon Pharms Inc · 1 drug in Heart Failure
  5. Merck & Co. · 1 drug in Heart Failure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Heart Failure:

Cite this brief

Drug Landscape (2026). Heart Failure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/heart-failure. Accessed 2026-05-14.

Related